AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

GDRX · NASDAQ · Medical - Healthcare Information Services

GoodRx

Matches consumers with prescription prices, discounts, subscriptions and manufacturer affordability services.

$3.53

After-hours close−0.02 (−0.42%)

At close$3.55(+1.00%)

Something off on this page? Send us feedback.

Profile

GoodRx Holdings, Inc.GDRXHealth Care

Helps U.S. consumers compare prescription prices and use savings codes at local and mail-order pharmacies. Transaction fees from PBMs, manufacturers and pharmacies remain the primary engine, alongside subscription and pharma-direct offerings.

Built around free web and app tools, the U.S. marketplace lets consumers compare local and mail-order prescription prices and obtain discounts. The tools serve both insured and uninsured consumers. It earns partner fees when prescriptions are filled using GoodRx codes, while subscriptions and pharma-direct offerings broaden the affordability platform.

A telehealth expansion added online medical visits, prescriptions and lab-test access for routine issues. Prescription transactions remain the business's central revenue source across the United States. Operations depend on relationships with PBMs, manufacturers and pharmacies, while consumer health-information handling is shaped by an FTC privacy-enforcement order.

Company facts

CEOWendy Barnes

ListedSep 23, 2020

ExchangeNASDAQ

HeadquartersSanta Monica, CA

CountryUnited States

Employees697

CIK0001809519

ISINUS38246G1085

Key statistics

Market cap$1.22B

EPS (ttm)$0.0425

P/E (ttm)83.06

ROE2.6%

P/B1.85

P/S1.56

Dividend yield—

Beta1.40vs XLV 0.30

Year to date +28.9% · Average volume (30d) 1.7M

Analysts

Price target, next 12 months$4.00+13.3%Median of 24 analysts · vs the Aug 28 close

ConsensusHold9 of 24 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $3.53

High$5.00+41.6%

Median$4.00+13.3%

Low$3.75+6.2%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 20, 2026	Barclays	Reiterate	Underweight	$3	$4
Aug 13, 2026	UBS	Reiterate	Neutral		$3.75
Aug 7, 2026	Goldman Sachs	Reiterate	Neutral	$3.50	$4
Aug 6, 2026	Leerink Partners	Target		$3	$5
May 8, 2026	Goldman Sachs	Target		$3	$3.50

Earnings

EPS

Estimate$0.08

ReportedDue Nov 3, 2026

Revenue

Estimate$202.4M

ReportedDue Nov 3, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 5, 2026Q2 FY26	$0.08	$0.08	+0.4%	$193.2M	$200.4M	+3.7%	+13.76%
May 6, 2026Q1 FY26	$0.07	$0.07	0.0%	$185.4M	$194.0M	+4.6%	+10.51%
Feb 25, 2026Q4 FY25	$0.09	$0.09	0.0%	$193.3M	$194.8M	+0.8%	−18.78%
Nov 4, 2025Q3 FY25	$0.09	$0.08	−11.1%	$193.3M	$196.0M	+1.4%	+2.15%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$203.0M	$203.1M	$196.0M	$194.8M	$194.0M	$200.4M
Gross profit	$189.6M	$170.0M	$182.6M	$177.3M	$152.1M	$179.4M
Operating income	$23.4M	$27.7M	$14.6M	$22.7M	$19.5M	$23.6M
Net income	$11.1M	$12.8M	$1.1M	$5.4M	$1.2M	$8.5M
Diluted EPS	$0.03	$0.04	$0.00	$0.02	$0.00	$0.02
Gross margin	93.4%	83.7%	93.2%	91.0%	78.4%	89.5%
Operating margin	11.5%	13.6%	7.5%	11.6%	10.1%	11.8%

Fiscal years (4-quarter sums)FY21 $745.4M · FY22 $766.6M · FY23 $750.3M · FY24 $792.3M · FY25 $796.9M

Revenue by product · Q2 FY26

Prescription Transactions Revenue$106.4M · 77%

Subscription Revenue$28.5M · 21%

Other Revenue$3.9M · 3%

Balance sheet, Jun 30, 2026Cash & short-term investments $296.1M · Total debt $539.0M · Total assets $2.34B · Shareholders' equity $647.6M

Dividends

No dividends on record.

Ownership

Institutions 34.12%118.27M sharesInsiders 13.32%46.15M sharesOther 52.56%182.20M shares

Shares outstanding 346.63M · Float 285.46M · 82.4% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Francisco Partners GP IV Management Limited	52.58M	32.90%	13D	Aug 26, 2026
Idea Men, LLC · director, 10 percent owner:	43.16M	12.45%	Form 4	Mar 21, 2025
SEA VII Management, LLC	8.91M	8.28%	13D	Sep 8, 2025
LSV Asset Management	4.98M	1.44%	13F	May 11, 2026
The Bank of Nova Scotia	4.75M	5.80%	13D/G	Oct 10, 2024

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 26, 2026	Francisco Partners Iv, L.P.	10 percent owner	−856,867	$3.51
Aug 25, 2026	Francisco Partners Iv, L.P.	10 percent owner	−127,273	$3.44
Aug 24, 2026	Francisco Partners Iv, L.P.	10 percent owner	−143,594	$3.46
Aug 21, 2026	Francisco Partners Iv, L.P.	10 percent owner	−274,717	$3.50
Aug 20, 2026	Francisco Partners Iv, L.P.	10 percent owner	−447,259	$3.52